Stoking Functional Copies of Genes to Compensate for Mutated Ones
RARECast - Ein Podcast von RARECast - Donnerstags
Kategorien:
Ed Kaye, CEO of Stoke Therapeutics, discusses the company’s platform technology to address diseases in which people have one functional copy of a gene and one mutated copy, how it works, and its lead program in Dravet syndrome.
